摘要
CardiovascularimmunologyresearchinWuhanUnionHospitalbeganin1991.Anti-heartantibodiesindilatedcardiomyopathyandacuteviralmyocarditisbegantobereportedfrom1993.ItwasfoundthatanewautoantibodyagainstL-typecalciumchannelresultsinventriculartachycardiaandsuddendeathinpatientswithdilatedcardiomyopathy.ThroughtheInterventionStudyofDiltiazeminDilatedCardiomyopathy,diltiazemwasverifiedtoreducemortalityandthechronicheartfailurehospitalizationratesignificantlyinpatientswithdilatedcardiomyopathy.TheautoantibodiesagainstangiotensinIIreceptortype1andα1-adrenoceptorwereassociatedwiththeincreasedrecurrenceofanddeathfromstrokeinhypertensivepatients.Throughmanyclinicalandexperimentalstudies,thefunctionalimbalanceofT-cellsubsetswassuggestedtomediatemyocardialinjuryandchronicheartfailure,whichprovidedanewtheoreticalbasisforimmunoregulationtherapyforheartfailure.Thefirstantihypertensivepolypeptidevaccine(ATRQβ-001)wasinvented.Inadditiontotheseachievements,therewillbemoreresearchoncardiovascularimmunologyinWuhanUnionHospitalinthefuture.
出版日期
2017年11月06日(中国期刊网平台首次上网日期,不代表论文的发表时间)